Case–control study of oral glucose‐lowering drugs in combination with long‐acting insulin and the risks of incident myocardial infarction and incident stroke

The use of oral glucose‐lowering therapies with insulin is common, but the cardiovascular effects are largely unknown. Among users of long‐acting insulin, we conducted a population‐based case–control study to evaluate the incident myocardial infarction (MI) and incident stroke risks associated with the use of sulfonylureas and the use of metformin.

[1]  P. Light,et al.  Cardiovascular safety of sulphonylureas: over 40 years of continuous controversy without an answer , 2015, Diabetes, obesity & metabolism.

[2]  S. Hennessy,et al.  Metformin use reduction in mild to moderate renal impairment: possible inappropriate curbing of use based on food and drug administration contraindications. , 2015, JAMA internal medicine.

[3]  T. Brennan,et al.  Initial choice of oral glucose-lowering medication for diabetes mellitus: a patient-centered comparative effectiveness study. , 2014, JAMA internal medicine.

[4]  F. Sellke,et al.  Metformin mitigates apoptosis in ischemic myocardium. , 2014, The Journal of surgical research.

[5]  S. Schneeweiss,et al.  Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations , 2014, Diabetologia.

[6]  Michael J. MacDonald,et al.  Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase , 2014, Nature.

[7]  D. Wysowski,et al.  Use of Antidiabetic Drugs in the U.S., 2003–2012 , 2014, Diabetes Care.

[8]  J. Shaw,et al.  Global estimates of diabetes prevalence for 2013 and projections for 2035. , 2014, Diabetes Research and Clinical Practice.

[9]  M. Monami,et al.  Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials , 2013, Diabetes, obesity & metabolism.

[10]  S. Engel,et al.  Sulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysis , 2013, Diabetic medicine : a journal of the British Diabetic Association.

[11]  A. Goto,et al.  Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis , 2013, BMJ.

[12]  D. Nathan,et al.  Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) , 2013, Diabetes Care.

[13]  G. Rena,et al.  Molecular mechanism of action of metformin: old or new insights? , 2013, Diabetologia.

[14]  S. Lai,et al.  Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease , 2013, Diabetes Care.

[15]  S. Inzucchi,et al.  Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2013, Diabetologia.

[16]  B. Viollet,et al.  Biguanides suppress hepatic glucagon signaling by decreasing production of cyclic AMP , 2016 .

[17]  Robert A Greevy,et al.  Comparative Effectiveness of Sulfonylurea and Metformin Monotherapy on Cardiovascular Events in Type 2 Diabetes Mellitus , 2012, Annals of Internal Medicine.

[18]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach , 2012, Diabetes Care.

[19]  A. Vaag,et al.  Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses , 2012, BMJ : British Medical Journal.

[20]  F. Gueyffier,et al.  Reappraisal of Metformin Efficacy in the Treatment of Type 2 Diabetes: A Meta-Analysis of Randomised Controlled Trials , 2012, PLoS medicine.

[21]  J. Leahy.  Insulin therapy in type 2 diabetes mellitus. , 2012, Endocrinology and metabolism clinics of North America.

[22]  Mark Woodward,et al.  Severe hypoglycemia and risks of vascular events and death. , 2010, The New England journal of medicine.

[23]  J. Danesh,et al.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.

[24]  V. Fonseca,et al.  Hypoglycemia, Diabetes, and Cardiovascular Events , 2010, Diabetes Care.

[25]  B. Psaty,et al.  Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study , 2010, BMJ : British Medical Journal.

[26]  A. Donker,et al.  Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. , 2009, Archives of internal medicine.

[27]  B. Frier,et al.  Vascular disease and diabetes: is hypoglycaemia an aggravating factor? , 2008, Diabetes/metabolism research and reviews.

[28]  S. Jha,et al.  Acute Metformin Therapy Confers Cardioprotection Against Myocardial Infarction Via AMPK-eNOS–Mediated Signaling , 2008, Diabetes.

[29]  B. Frier,et al.  Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. , 2005, Diabetes care.

[30]  R. Stolk,et al.  Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. , 2004, The Cochrane database of systematic reviews.

[31]  M. Nauck,et al.  Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? , 2003, Heart.

[32]  F. Ashcroft,et al.  Sulfonylurea stimulation of insulin secretion. , 2002, Diabetes.

[33]  Benjamin Cheong,et al.  Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. , 2002, Diabetes care.

[34]  B. Oeseburg,et al.  Metformin improves cardiac functional recovery after ischemia in rats. , 2002, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[35]  I. Deary,et al.  Symptoms of hypoglycaemia in people with diabetes , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[36]  N. Standen,et al.  Glimepiride, a Novel Sulfonylurea, Does Not Abolish Myocardial Protection Afforded by Either Ischemic Preconditioning or Diazoxide , 2001, Circulation.

[37]  B M Psaty,et al.  Antihypertensive drug therapies and the risk of ischemic stroke. , 2001, Archives of internal medicine.

[38]  David E. Booth,et al.  Analysis of Incomplete Multivariate Data , 2000, Technometrics.

[39]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[40]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[41]  R. Kronmal,et al.  Assessing the sensitivity of regression results to unmeasured confounders in observational studies. , 1998, Biometrics.

[42]  B. Psaty,et al.  Duration of estrogen replacement therapy in relation to the risk of incident myocardial infarction in postmenopausal women. , 1997, Archives of internal medicine.

[43]  T. Raghunathan,et al.  The risk of myocardial infarction associated with antihypertensive drug therapies. , 1995, JAMA.

[44]  R. Herings,et al.  Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme , 1995, The Lancet.

[45]  C. Toombs,et al.  Limitation of infarct size in the rabbit by ischaemic preconditioning is reversible with glibenclamide. , 1993, Cardiovascular research.

[46]  G. Grover,et al.  Role of Myocardial ATP‐Sensitive Potassium Channels in Mediating Preconditioning in the Dog Heart and Their Possible Interaction With Adenosine A1‐Receptors , 1992, Circulation.

[47]  I. Macdonald,et al.  Beta-adrenoceptor blockade and hypoglycaemia. A randomised, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects. , 1990, British journal of clinical pharmacology.

[48]  O. Miettinen,et al.  Estimability and estimation in case-referent studies. , 1976, American journal of epidemiology.

[49]  A. Vaag,et al.  Sulfonylurea in combination with insulin is associated with increased mortality compared with a combination of insulin and metformin in a retrospective Danish nationwide study , 2014, Diabetologia.

[50]  D. Wysowski,et al.  Use of Antidiabetic Drugs in the , 2014 .

[51]  H. Kawabata,et al.  Cardioprotection by metformin is abolished by a nitric oxide synthase inhibitor in ischemic rabbit hearts. , 2003, Hypertension research : official journal of the Japanese Society of Hypertension.

[52]  B. Psaty,et al.  The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. , 1994, Archives of internal medicine.

[53]  C. Meinert,et al.  A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. , 1970, Diabetes.